Pharmafile Logo
Pharmafocus logo
Advanced Search

primary biliary cholangitis

Showing 5 posts of 5 posts found.

FDA approves drug for primary biliary cholangitis

August 15, 2024
Research and Development FDA Approval, FDA approva;, Hepatology, liver, primary biliary cholangitis

Accelerated approval has been granted for Gilead Science’s Livdelzi (seladelpar) to treat primary biliary cholangitis (PBC) by the US Food …

News

Calliditas Therapeutics announces positive phase 2b data in Primary Biliary Cholangitis trial

July 26, 2024
Research and Development Calliditas, Hepatology, clinical trials, elevated liver stiffness, primary biliary cholangitis

 Calliditas Therapeutics AB today announced that the phase 2b TRANSFORM trial met its primary endpoint. The trial showed statistically significant …

News

Gilead shares results from two-year analysis of phase 3 study in primary biliary cholangitis

June 5, 2024
Research and Development Gilead, Hepatology, clinical trials, primary biliary cholangitis, seladelpar

Gilead has announced two-year interim results from the ongoing ASSURE study of investigational seladelpar for the treatment of primary biliary …

News

NICE approves first biliary cholangitis drug in 20 years

March 2, 2017
Sales and Marketing Intercept Pharmaceuticals, intercept, liver disease, ocaliva, primary biliary cholangitis

Intercept Pharmaceuticals has announced that Ocaliva (obeticholic acid) has been approved by the National Institute for Health and Care Excellence …

News
ema_building_face_web

EMA grants conditional approval for biliary cholangitis treatment

October 17, 2016
Sales and Marketing EMA, intercept, ocaliva, primary biliary cholangitis

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has voiced its approval of Intercept’s Ocaliva …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026